Trulieve Cannabis Corp. Subordi — Vertically Integrated U.S. Cannabis Leader Trading at a Discount to Asset Value

Trulieve Cannabis Corp. is a vertically integrated cannabis company operating primarily in the United States, with a corporate structure that includes a subordinate voting share class (ticker TRLV). The company cultivates cannabis, manufactures derivative products (edibles, concentrates, vapes, topicals), and sells through its own branded retail dispensaries.

How it makes money:

• Retail dispensary sales — the largest revenue contributor, driven by foot traffic at company-owned stores, concentrated heavily in Florida.
• Wholesale — sales of cultivated flower and manufactured products to third-party licensed retailers in select states.
• Branded product licensing and ancillary operations — a smaller but growing contributor.

Customers: Primarily medical cannabis patients in Florida and adult-use consumers in states where recreational sales are legal. The customer base is retail, direct-to-consumer, with loyalty programs driving repeat visits.

Scale: With a $2.1B market capitalization and 170.16M shares outstanding, Trulieve ranks among the largest publicly traded multi-state operators by revenue. Its public float of 167.89M shares represents the overwhelming majority of shares outstanding, indicating high effective liquidity despite the subordinate voting structure.

Near term (12–18 months):

• Continued Florida medical market share defense and store-level productivity gains.
• Cost reduction across cultivation and manufacturing, improving gross margin.
• Debt reduction funded by operating cash flow, lowering interest expense.

Medium term (2–5 years):

• Florida adult-use legalization would be the single largest revenue driver, leveraging existing infrastructure with minimal new capital.
• Expansion of higher-margin derivative and branded product mix, shifting revenue away from low-margin flower.
• Potential federal rescheduling reducing the 280E tax burden, directly expanding net income.
• Selective footprint optimization in additional limited-license states.

Growth is not dependent on any single catalyst, but the magnitude of upside is heavily contingent on the regulatory path.

Narrative: The reported EPS of $-2.44 is the headline number most visible to screens, but it materially overstates the cash burn of the business. Under Section 280E, cannabis companies cannot deduct ordinary business expenses, inflating taxable income and depressing GAAP net income. The cash generation story is far healthier than the earnings line suggests, and the market's focus on GAAP EPS creates the valuation inefficiency central to the thesis.

Market size / TAM: The U.S. legal cannabis market is estimated in the tens of billions of dollars annually, with Florida representing one of the largest single-state medical markets. Federal prohibition caps the addressable market by excluding interstate commerce and institutional capital.

Competitive positioning: Trulieve's vertically integrated model and Florida density give it cost advantages over smaller operators. However, it competes with well-capitalized multi-state operators and, in Florida, with a limited set of license holders.

Named comparables:

• Curaleaf Holdings — largest U.S. MSO by revenue, broad multi-state footprint.
• Green Thumb Industries — strong cash generation, branded product focus.
• Verano Holdings — multi-state operator with concentrated retail presence.
• Cresco Labs — wholesale-heavy model, recent consolidation activity.

Relative to these peers, Trulieve's Florida concentration is both its greatest strength (defensible cash flow) and its greatest risk (regulatory and market concentration).

DCF discussion: A discounted cash flow analysis is highly sensitive to the tax regime assumption. Under current 280E treatment, cash flows are materially suppressed; under a rescheduled or descheduled scenario, unlevered free cash flow would expand sharply, raising fair value. Given the binary nature of the regulatory catalyst, a probability-weighted DCF — assigning partial credit to reform scenarios — is more appropriate than a single-path model. Using the current price of $11.07 as the market-implied base case, the DCF suggests the market assigns minimal probability to reform.

Comparable-company multiples:

Cannabis multiples are structurally depressed versus other consumer sectors due to federal illegality, limited institutional ownership, and 280E tax drag. TRLV trades broadly in line with MSO peers, with a modest discount justified by Florida concentration risk but arguably over-penalized given its cash generation.

• Regulatory and legal risk: Federal prohibition, potential adverse enforcement, and the failure of reform legislation would sustain the 280E tax burden and cap institutional capital inflows.
• State concentration risk: Heavy reliance on Florida means adverse state-level rule changes, license expansion, or pricing pressure would disproportionately impact results.
• Tax risk: Continued 280E treatment suppresses net income and free cash flow; any adverse IRS interpretation increases the drag.
• Leverage and refinancing risk: Cannabis operators face elevated borrowing costs and limited access to traditional credit markets, creating refinancing exposure.
• Volatility and liquidity risk: A beta of 1.76 indicates high price volatility, and despite strong average volume of 1.27M shares, the sector can experience sharp drawdowns on regulatory headlines.